Global Veterinary Anti-Infective Market, By Species Type (Livestock Animals, Companion Animals), Drug Class (Antimicrobial Agents, Antiviral Agents, Antifungal Agents, Antiparasitic Agents, Others), Mode of Administration (Oral, Parenteral, Topical), Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies, Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Veterinary Anti-Infective Market
Data Bridge Market Research analyses that the veterinary anti-infective market is growing at a CAGR of 7.30% in the forecast period of 2022-2029.
Anti-infective are medicines that work to treat infections in animals by veterinarian, they include antibacterials, antivirals, antifungals and antiparasitic medications.
The pet adoption coupled with rising concerns regarding pet health is the major factor accelerating the growth of the veterinary anti-infective market. Furthermore, prevalence of bacterial infection, especially in dogs and demand for improved nutrition, especially functional animal protein are also expected to drive the growth of the veterinary anti-infective market. However, the high price and reoccurrence of infection restrains the veterinary anti-infective market, whereas, the side effects of certain drugs in animals will challenge market growth.
In addition, biologics and specialty care will create ample opportunities for the veterinary anti-infective market.
This veterinary anti-infective market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on veterinary anti-infective market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Veterinary Anti-Infective Market Scope and Market Size
The veterinary anti-infective market is segmented on the basis of species type, drug class, mode of administration and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of species type, the veterinary anti-infective market is segmented into livestock animals, companion animals.
- On the basis of mode of administration, the veterinary anti-infective market is segmented into oral, parenteral, topical
- On the basis of distribution channel, the veterinary anti-infective market is segmented into veterinary hospitals, veterinary clinics, pharmacies, others.
- On the basis of drug class, the veterinary anti-infective market is segmented into antimicrobial agents, antiviral agents, antifungal agents, antiparasitic agents, others. Antimicrobial Agents is further segmented into tetracyclines, penicillins, cephalosporins, macrolides, quinolones, others.
Veterinary Anti-Infective Market Country Level Analysis
The veterinary anti-infective market is analysed and market size insights and trends are provided by country, drug class, species type, mode of administration and distribution channel as referenced above.
The countries covered in the veterinary anti-infective market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the veterinary anti-infective market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the rise in pet ownership and growing demand for improved nutrition, especially functional animal protein in this region. Asia-Pacific on the other hand is projected to exhibit the highest growth rate during the forecast period due to the promotion of small animal care in this region.
The country section of the veterinary anti-infective market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The veterinary anti-infective market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for veterinary anti-infective market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the veterinary anti-infective market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Veterinary Anti-Infective Market Share Analysis
The veterinary anti-infective market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to veterinary anti-infective market.
Some of the major players operating in the veterinary anti-infective market report are Virbac., Ceva, Hester Biosciences Limited, Elanco, HIPRA, CHINA ANIMAL HUSBANDRY GROUP, Phibro Animal Health Corporation., Intervet Inc., Vetoquinol, Biogénesis Bagó, Boehringer Ingelheim International GmbH., jinyu Group, Ringpu, Zoetis, Inc., Pfizer Inc., Mars, Incorporated, Lilly, Cargill, Incorporated, Takeda Pharmaceutical Company Limited., Indovax, among other
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
List of Table
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL VETERINARY ANTI-INFECTIVE MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL VETERINARY ANTI-INFECTIVE MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL VETERINARY ANTI-INFECTIVE MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7. EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8. MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9. REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10. PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
11. MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICTION
11.3 PHARMACOLOGICAL CLASS OF THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 DRUG ROUTE OF ADMINISTRATION
11.10 DOSING FREQUENCY
11.11 DRUG INSIGHT
11.12 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.12.1 FORECAST MARKET OUTLOOK
11.12.2 CROSS COMPETITION
11.12.3 THERAPEUTIC PORTFOLIO
11.12.4 CURRENT DEVELOPMENT SCENARIO
12. MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13. R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14. MARKET OVERVIEW
14.1 DRIVERS
14.2 RESTRAINTS
14.3 OPPORTUNITIES
14.4 CHALLENGES
15. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY DRUGS CLASS
15.1 OVERVIEW
15.2 ANTIMICROBIAL AGENTS
15.2.1 BETA-LACTAMS
15.2.1.1. PENICILLINS
15.2.1.1.1. NATURAL PENICILLINS
15.2.1.1.2. AMDINOPENICILLINS
15.2.1.1.3. AMINOPENICILLINS
15.2.1.1.4. CARBOXYPENICILLINS
15.2.1.1.5. UREIDO PENICILLIN
15.2.1.1.6. PHENOXYPENICILLINS
15.2.1.1.7. ANTISTAPHYLOCOCCAL PENICILLINS
15.2.1.1.8. OTHERS
15.2.1.2. CEPHALOSPORINS
15.2.1.2.1. CEPHALOTHIN
15.2.1.2.2. CEFAMANDOLE
15.2.1.2.3. CEFATAXIME
15.2.1.2.4. OTHERS
15.2.1.3. CEPHAMYCINS
15.2.2 GLYCOPEPTIDES
15.2.2.1. VANCOMYCIN
15.2.2.2. OTHERS
15.2.3 PROTEIN SYNTHESIS INHIBITORS
15.2.3.1. TETRACYCLINES
15.2.3.1.1. CHLORTETRACYCLINE
15.2.3.1.2. DOXYCYCLINE
15.2.3.1.3. OXYTETRACYCLINE
15.2.3.2. MACROLIDES
15.2.3.3. QUINOLONES
15.2.3.4. LINCOSAMIDES
15.2.3.5. OTHERS
15.2.4 DNA SYNTHESIS INHIBITORS
15.2.4.1. NOVOBIOCIN
15.2.4.2. QUINOLONES
15.2.4.3. METRONIDAZOLE
15.2.5 POLYMERASE INHIBITORS
15.2.5.1. RIFAMYCINS
15.2.5.2. OTHERS
15.2.6 FOLIC ACID INHIBITORS
15.2.6.1. SULFONAMIDES
15.2.6.1.1. SULFACHLORPYRIDAZINE
15.2.6.1.2. SULFADIAZINE
15.2.6.1.3. SULFADIMERAZIN
15.2.6.1.4. SULFADIMIDINE
15.2.6.1.5. OTHERS
15.2.6.2. TRIMETHOPRIM
15.2.7 BACITRACIN
15.2.8 FOSFOMYCIN
15.2.9 AMINOGLYCOSIDES
15.2.10 AMINOCYCLITOL
15.2.11 AMINOGLYCOSIDES
15.2.11.1. GENTAMICIN
15.2.11.2. TOBRAMYCIN
15.2.11.3. AMIKACIN
15.2.11.4. STREPTOMYCIN
15.2.11.5. KANMYCIN
15.2.11.6. OTHERS
15.2.12 BICYCLOMYCIN
15.2.13 IONOPHORES
15.2.14 ORTHOSOMYCINS
15.2.15 PHENICOLS
15.2.16 PLEUROMUTILINS
15.2.17 OTHERS (IF ANY)
15.3 ANTIVIRAL AGENTS
15.3.1 IDOXURIDINE
15.3.2 TRIFLURIDINE
15.3.3 ACYCLOVIR
15.3.4 GANCICLOVIR
15.3.5 OSELTAMIVIR
15.3.6 INTERFERON ALFA-2
15.3.7 OTHERS (IF ANY)
15.4 ANTIFUNGAL AGENTS
15.4.1 POLYENES
15.4.2 AZOLES
15.4.3 ALLYLAMINES
15.4.4 NUCLEOSIDE ANALOGS
15.4.5 ECHINOCANDINS
15.4.6 OTHERS (IF ANY)
15.5 ANTIPARASITIC AGENTS
15.5.1 ISOXAZOLINES
15.5.2 IVERMECTIN
15.5.3 MILBEMYCIN
15.5.4 MOXIDECTIN
15.5.5 SELAMECTIN
15.5.6 LUFENURON
15.5.7 NITENPYRAM
15.5.8 SPINOSAD
15.5.9 SODIUM STIBOGLUCONATE
15.5.10 OTHERS
15.6 OTHERS
16. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY DOSAGE FORM
16.1 OVERVIEW
16.2 SOLID
16.2.1 TABLET
16.2.2 POWDER
16.2.3 OTHERS
16.3 SEMI-SOLID
16.3.1 GEL
16.3.2 CREAM
16.3.3 OTHERS
16.4 LIQUID
16.4.1 SYRUP
16.4.2 SUSPENSION
16.4.3 BOLUS
16.4.4 SOLUTION
16.4.5 OTHERS
16.5 OTHERS
17. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY ROUTE OF ADMINISTRATION
17.1 OVERVIEW
17.2 ORAL
17.2.1 TABLET
17.2.2 PILLS
17.2.3 OTHERS
17.3 PARENTERAL
17.3.1 INTRAVENOUS
17.3.2 SUBCUTANEOUS
17.3.3 OTHERS
17.4 TOPICAL
17.5 OTHERS
18. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY DRUG TYPE
18.1 OVERVIEW
18.2 BRANDED
18.3 GENERICS
19. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY SPECIES TYPE
19.1 OVERVIEW
19.2 LIVESTOCK ANIMALS
19.2.1 BY TYPE
19.2.1.1. POULTRY
19.2.1.2. SWINE
19.2.1.3. CATTLE
19.2.1.4. SHEEP & GOATS
19.2.1.5. FISH
19.2.1.6. OTHERS
19.2.2 BY INFECTION TYPE
19.2.2.1. BACTERIAL INFECTION
19.2.2.2. VIRAL INFECTION
19.2.2.3. FUNGAL INFECTION
19.2.2.4. PARASITIC INFECTIONS
19.2.2.5. OTHERS
19.3 COMPANION ANIMALS
19.3.1 BY TYPE
19.3.1.1. DOGS
19.3.1.2. CATS
19.3.1.3. HORSES
19.3.1.4. OTHERS
19.3.2 BY INFECTION TYPE
19.3.2.1. BACTERIAL INFECTION
19.3.2.2. VIRAL INFECTION
19.3.2.3. FUNGAL INFECTION
19.3.2.4. PARASITIC INFECTIONS
19.3.2.5. OTHERS
20. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY APPLICATIONS
20.1 OVERVIEW
20.2 BACTERIAL INFECTION
20.2.1 SKIN INFECTIONS
20.2.2 RESPIRATORY INFECTIONS
20.2.3 GASTROINTESTINAL INFECTIONS
20.2.4 URINARY TRACT INFECTIONS (UTIS)
20.2.5 REPRODUCTIVE TRACT INFECTIONS
20.2.6 OTHERS
20.3 VIRAL INFECTION
20.3.1 PARVOVIRUS
20.3.2 PANLEUKOPENIA VIRUS
20.3.3 RABIES
20.3.4 HERPESVIRUS
20.3.5 INFLUENZA VIRUS
20.3.6 OTHERS
20.4 FUNGAL INFECTION
20.4.1 ASPERGILLOSIS
20.4.2 HISTOPLASMOSIS
20.4.3 COCCIDIOIDOMYCOSIS
20.4.4 BLASTOMYCOSIS
20.4.5 CRYPTOCOCCOSIS
20.4.6 DERMATOPHYTES (RINGWORMS)
20.4.7 MALESSEZIA DERMATITIS
20.5 PARASITIC INFECTIONS
20.6 OTHERS
21. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 VETERINARY HOSPITALS
21.2.1 PUBLIC
21.2.2 PRIVATE
21.3 VETERINARY CLINICS
21.4 PHARMACY
21.4.1 HOSPITAL PHARMACY
21.4.2 ONLINE PHARMACY
21.4.3 OTHERS
21.5 OTHERS
22. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, BY GEOGRAPHY
GLOBAL VETERINARY ANTI-INFECTIVE MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 NORTH AMERICA
23.1.1 U.S.
23.1.2 CANADA
23.1.3 MEXICO
23.2 EUROPE
23.2.1 GERMANY
23.2.2 U.K.
23.2.3 ITALY
23.2.4 FRANCE
23.2.5 SPAIN
23.2.6 RUSSIA
23.2.7 SWITZERLAND
23.2.8 TURKEY
23.2.9 BELGIUM
23.2.10 NETHERLANDS
23.2.11 DENMARK
23.2.12 SWEDEN
23.2.13 POLAND
23.2.14 NORWAY
23.2.15 FINLAND
23.2.16 REST OF EUROPE
23.3 ASIA-PACIFIC
23.3.1 JAPAN
23.3.2 CHINA
23.3.3 SOUTH KOREA
23.3.4 INDIA
23.3.5 SINGAPORE
23.3.6 THAILAND
23.3.7 INDONESIA
23.3.8 MALAYSIA
23.3.9 PHILIPPINES
23.3.10 AUSTRALIA
23.3.11 NEW ZEALAND
23.3.12 VIETNAM
23.3.13 TAIWAN
23.3.14 REST OF ASIA-PACIFIC
23.4 SOUTH AMERICA
23.4.1 BRAZIL
23.4.2 ARGENTINA
23.4.3 REST OF SOUTH AMERICA
23.5 MIDDLE EAST AND AFRICA
23.5.1 SOUTH AFRICA
23.5.2 EGYPT
23.5.3 BAHRAIN
23.5.4 UNITED ARAB EMIRATES
23.5.5 KUWAIT
23.5.6 OMAN
23.5.7 QATAR
23.5.8 SAUDI ARABIA
23.5.9 REST OF MIDDLE EAST AND AFRICA
23.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, SWOT AND DBMR ANALYSIS
25. GLOBAL VETERINARY ANTI-INFECTIVE MARKET, COMPANY PROFILE
25.1 VIRBAC
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 CEVA
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 HESTER BIOSCIENCES LIMITED
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 HIPRA
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 PHIBRO ANIMAL HEALTH CORPORATION
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 INTERVET (PTY) LTD (MERCK & CO., INC)
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 VETOQUINOL
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 BIOGÉNESIS BAGÓ
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.10 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 ZOETIS SERVICES LLC
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 NEOGEN CORPORATION
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 HUVEPHARMA NV
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 INTAS PHARMACEUTICALS
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 ELANCO
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 ECO - ANIMAL HEALTH LTD.
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 KEMIN INDUSTRIES, INC.
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 MANKIND PHARMA
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 NEXGEN PHARMACEUTICALS (LGM PHARMA)
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.20 BIOLOGISCHE HEILMITTEL HEEL GMBH
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
25.21 MERRITT PHARMA LTD
25.21.1 COMPANY OVERVIEW
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPMENTS
25.22 ANI HEALTHCARE
25.22.1 COMPANY OVERVIEW
25.22.2 REVENUE ANALYSIS
25.22.3 GEOGRAPHIC PRESENCE
25.22.4 PRODUCT PORTFOLIO
25.22.5 RECENT DEVELOPMENTS
25.23 GMT PHARMA
25.23.1 COMPANY OVERVIEW
25.23.2 REVENUE ANALYSIS
25.23.3 GEOGRAPHIC PRESENCE
25.23.4 PRODUCT PORTFOLIO
25.23.5 RECENT DEVELOPMENTS
25.24 STANEX DRUGS AND CHEMICALS PVT LTD
25.24.1 COMPANY OVERVIEW
25.24.2 REVENUE ANALYSIS
25.24.3 GEOGRAPHIC PRESENCE
25.24.4 PRODUCT PORTFOLIO
25.24.5 RECENT DEVELOPMENTS
25.25 DECHRA PHARMACEUTICALS PLC
25.25.1 COMPANY OVERVIEW
25.25.2 REVENUE ANALYSIS
25.25.3 GEOGRAPHIC PRESENCE
25.25.4 PRODUCT PORTFOLIO
25.25.5 RECENT DEVELOPMENTS
25.26 KYORITSUSEIYAKU CORPORATION
25.26.1 COMPANY OVERVIEW
25.26.2 REVENUE ANALYSIS
25.26.3 GEOGRAPHIC PRESENCE
25.26.4 PRODUCT PORTFOLIO
25.26.5 RECENT DEVELOPMENTS
25.27 OUROFINO SAÚDE ANIMAL
25.27.1 COMPANY OVERVIEW
25.27.2 REVENUE ANALYSIS
25.27.3 GEOGRAPHIC PRESENCE
25.27.4 PRODUCT PORTFOLIO
25.27.5 RECENT DEVELOPMENTS
25.28 BIMEDA, INC. (BIMEDA HOLDINGS PLC)
25.28.1 COMPANY OVERVIEW
25.28.2 REVENUE ANALYSIS
25.28.3 GEOGRAPHIC PRESENCE
25.28.4 PRODUCT PORTFOLIO
25.28.5 RECENT DEVELOPMENTS
25.29 ANIMALCARE GROUP PLC
25.29.1 COMPANY OVERVIEW
25.29.2 REVENUE ANALYSIS
25.29.3 GEOGRAPHIC PRESENCE
25.29.4 PRODUCT PORTFOLIO
25.29.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26. RELATED REPORTS
27. CONCLUSION
28. QUESTIONNAIRE
29. ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
